NeuroPace Slashes FY26 Revenue Outlook to $91-92M as Q3 Sales Fall 1.1%
NPCE is trading near its 52-week low of $11.9 (1.0% above the low).
Summary
NeuroPace cut full-year 2026 revenue guidance to $91-92 million from $99.5-101.5 million, roughly an 8% trim at the midpoint, after Q3 total revenue fell 1.1% year-over-year to $23.1 million and Q3 EPS came in at USD -0.1. RNS System revenue grew just 1.4% to $22.9 million, a sharp deceleration from the 17% growth reported in Q2. Management blamed the shortfall on a handful of large accounts and disruption from field-organization changes, and said Q4 scheduled cases have begun to recover. The company also lowered non-GAAP opex guidance to $85-86 million and widened its Adjusted EBITDA loss outlook to $8.5-9.5 million, though gross margin guidance rose to 83.0-83.5%. Cash and investments stood at $49.5 million against $59.2 million of long-term debt, so the slower growth path tightens the runway. On the pipeline, NeuroPace expects to submit its IGE PMA supplement amendment around year end following an October FDA meeting, has filed a Remote Care PMA supplement on a 180-day review, and started enrolling the AURORA adolescent study with data expected in early 2027.
At the time of this announcement, NPCE was trading at $12.02 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $412.6M. The 52-week trading range was $11.90 to $19.60. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: BusinessWire.